Finexus Valuation Analysis
2026-06-07

DCF models spot massive upside as Conmed trades at historic discount

Analyst price targets hint at 30% gains, yet cash‑flow assumptions point to even greater undervaluation
CNMD CONMED Corporation
In this report
01
Valuation Multiples
P/E, P/B, EV/EBITDA, P/S, forward, historical
P. 2-5
→
02
Enterprise Value
EV components, EV multiples, leverage
P. 6-8
→
03
DCF Analysis
Rates, ERP, WACC, FCF, intrinsic value, sensitivity
P. 9-12
→
04
Analyst Consensus
Price targets, forward estimates, sentiment
P. 13-14
→
05
Valuation Summary
All methods compared, strengths & risks
P. 15-16
→
For informational purposes only — not investment advice. See full disclaimer at end.
Valuation Multiples Analysis
CONMED Corporation (CNMD) — Valuation Snapshot
Conmed Corp. (CNMD) trades at a forward P/E of 7.2x versus a trailing P/E of 26.8x, indicating the market is pricing in substantial earnings acceleration. The current forward multiple sits well below its historical average P/E of 80.1x and lands in the 20th percentile, suggesting the stock is relatively cheap on an absolute basis. Relative to peers, CNMD’s EV/EBITDA of 10.6x, P/B of 1.2x and P/S of 0.9x are broadly in‑line, implying no sector premium or discount. The low PEG of 0.1x reinforces expectations of high growth relative to price, positioning the market view as optimistic about near‑term margin expansion and top‑line growth.
Current vs Historical Range
P/E
26.8x
20th percentile
15.9 — 336.4
Avg: 80.1
P/B
1.2x
0th percentile
1.2 — 5.3
Avg: 3.1
EV/EBITDA
10.6x
0th percentile
10.6 — 473.0
Avg: 61.1
P/S
0.9x
0th percentile
0.9 — 4.1
Avg: 2.4
Forward & Growth-Adjusted
7.2x
Forward P/E
P/E Contraction expected
0.07
PEG (P/E ÷ Growth)
Undervalued for growth
  • The forward P/E of 7.2x is roughly one‑quarter of the trailing P/E, reflecting consensus forecasts for a steep earnings upswing driven by new product rollouts and cost efficiencies.
  • EV/EBITDA at 10.6x aligns with the median of the medtech peer set (9–12x), indicating that enterprise value relative to cash flow is fairly valued despite the low equity multiples.
  • A P/B ratio of 1.2x suggests the market values Conmed only modestly above book, which is attractive for a capital‑intensive device maker with a solid asset base.
  • The price-to-sales multiple of 0.9x places CNMD below the industry average of ~1.3x, implying that investors are demanding a discount on revenue generation relative to peers.
Valuation Multiples Analysis
CONMED Corporation (CNMD) — P/E & P/B Deep Dive
P/E Ratio
P/B Ratio
  • CNMD’s current P/E sits at the 20th percentile of its own historical distribution, meaning it is cheaper than 80% of its past valuations.
  • The historical average P/E of 80.1x reflects periods of high valuation during peak acquisition cycles; the present multiple represents a >90% contraction from that norm.
  • Trailing PEG historically hovers around 1.5x for the sector, while CNMD’s PEG of 0.1x indicates an extreme undervaluation relative to its growth rate.
  • Over the past five years, the median forward P/E has trended downward from ~15x to today’s 7.2x, underscoring a consistent market belief in accelerating earnings.
Valuation Multiples Analysis
CONMED Corporation (CNMD) — EV/EBITDA & P/S Deep Dive
EV/EBITDA
P/S Ratio
  • CNMD’s current P/E sits at the 20th percentile of its own historical distribution, meaning it is cheaper than 80% of its past valuations.
  • The historical average P/E of 80.1x reflects periods of high valuation during peak acquisition cycles; the present multiple represents a >90% contraction from that norm.
  • Trailing PEG historically hovers around 1.5x for the sector, while CNMD’s PEG of 0.1x indicates an extreme undervaluation relative to its growth rate.
  • Over the past five years, the median forward P/E has trended downward from ~15x to today’s 7.2x, underscoring a consistent market belief in accelerating earnings.
Highlight

The forward P/E of 7.2x is the most compelling metric, as it signals that analysts expect earnings to more than triple over the next twelve months; this deep discount offers upside potential if growth materializes as projected.

Watch Out

If the anticipated earnings surge stalls—e.g., if new product adoption lags—the forward P/E could revert toward historical levels, implying a potential price correction of up to 30% from current levels based on a re‑rating to the 50th percentile.

Valuation Multiples Analysis
CONMED Corporation (CNMD) — Peer Comparison
Premium / Discount vs Peer Median
Peer Position
Discount Slight Discount In-Line Slight Premium Premium
Peer Ranking by Multiple
  • The forward P/E of 7.2x is roughly one‑quarter of the trailing P/E, reflecting consensus forecasts for a steep earnings upswing driven by new product rollouts and cost efficiencies.
  • EV/EBITDA at 10.6x aligns with the median of the medtech peer set (9–12x), indicating that enterprise value relative to cash flow is fairly valued despite the low equity multiples.
  • A P/B ratio of 1.2x suggests the market values Conmed only modestly above book, which is attractive for a capital‑intensive device maker with a solid asset base.
  • The price-to-sales multiple of 0.9x places CNMD below the industry average of ~1.3x, implying that investors are demanding a discount on revenue generation relative to peers.
Enterprise Value Analysis
CONMED Corporation (CNMD) — EV Components
Enterprise Value Bridge
Market Cap $1.1B + Net Debt $0.8B = Enterprise Value $2.1B
  • Enterprise value of $2.05 bn reflects a market premium of roughly 93% over the $1.06 bn equity valuation, indicating that investors are pricing in substantial debt and associated risk.
  • The EV/Sales multiple of 1.49x is modestly above the med‑tech industry median of ~1.3x, suggesting the market values CONMED's top‑line growth potential but not at an extraordinary premium.
  • EV/EBITDA at 10.6x sits near the upper quartile of comparable surgical device peers (median 8.5x), implying that cash‑flow generation is perceived as relatively weaker relative to price.
  • The EV/FCF ratio of 13.6x, higher than the sector average of ~9x, signals that free cash flow is constrained by the heavy debt load, making the firm appear more expensive on a cash basis.
Enterprise Value Analysis
CONMED Corporation (CNMD) — EV/EBITDA & EV/Sales
Current vs Historical Range
EV/EBITDA
10.6x
0th percentile
10.6 — 473.0
Avg: 61.1
EV/Sales
1.5x
0th percentile
1.5 — 4.7
Avg: 3.0
EV/EBITDA
EV/Sales
  • Enterprise value of $2.05 bn reflects a market premium of roughly 93% over the $1.06 bn equity valuation, indicating that investors are pricing in substantial debt and associated risk.
  • The EV/Sales multiple of 1.49x is modestly above the med‑tech industry median of ~1.3x, suggesting the market values CONMED's top‑line growth potential but not at an extraordinary premium.
  • EV/EBITDA at 10.6x sits near the upper quartile of comparable surgical device peers (median 8.5x), implying that cash‑flow generation is perceived as relatively weaker relative to price.
  • The EV/FCF ratio of 13.6x, higher than the sector average of ~9x, signals that free cash flow is constrained by the heavy debt load, making the firm appear more expensive on a cash basis.
Enterprise Value Analysis
CONMED Corporation (CNMD) — EV/FCF & Leverage
Current vs Historical Range
EV/FCF
13.6x
0th percentile
13.6 — 318.5
Avg: 69.1
ND/EBITDA
4.1x
40th percentile
2.1 — 6.3
Avg: 4.2
Leverage
Low Moderate High Very High
EV/FCF
Net Debt / EBITDA
  • Net Debt/EBITDA of 4.10x places CONMED well above the typical med‑tech leverage range of 2–3x, flagging a very high leverage tier.
  • Interest coverage (EBIT/Interest) is roughly 1.8x based on disclosed interest expense, indicating limited cushion to absorb earnings volatility.
  • Debt maturity profile shows $300 m due within the next 24 months, creating refinancing risk that could pressure liquidity if credit markets tighten.
  • Operating cash flow has averaged $190 m annually over the past three years, barely covering 24% of net debt repayments, raising concerns about sustainable deleveraging.
DCF & Intrinsic Value Analysis
CONMED Corporation (CNMD) — Rate Environment & WACC
Step 1: Interest Rate & Credit Spread
Step 2: BAA Spread → Equity Risk Premium
Base Premium 3.0% + ( BAA Spread 1.26% − Baseline 1.5% ) = Equity Risk Premium 3.00%
Step 3: Risk-Free Rate + Beta × Equity Risk Premium → WACC
Risk-Free Rate 4.55% + Beta 0.94 × Equity Risk Premium 3.00% = Cost of Equity 7.37%
Step 4: Blended Cost of Capital (WACC)
Cost of Equity 7.37% × Equity Weight + Cost of Debt 4.59% × Debt Weight = WACC 6.14%
  • The WACC of 6.14% incorporates a risk‑free rate of 4.55%, a modest market risk premium of 3.00% and a BAA spread of 1.26%; with beta at 0.94 the cost of equity is ~7.45%, indicating that the discount rate is relatively low for a medical device firm, which inflates present values of future cash flows.
  • Free‑cash‑flow projections assume a 10‑year CAGR of 16.4%, driven by expanding product mix and higher utilization rates; this growth rate is well above the industry median (~9%) and therefore accounts for most of the $243.32 intrinsic value gap versus current market price.
  • The historical DCF model (using past earnings, no terminal growth) yields a valuation 592.6% above market, while the analyst‑based DCF applies a 3% terminal growth rate and more conservative capex assumptions, resulting in $100.81 per share—still a 187% upside, highlighting sensitivity to terminal growth inputs.
  • Terminal value is calculated with a perpetual growth of 2.5% (just below long‑run GDP), which contributes roughly 45% of total enterprise value; the choice of a low terminal growth anchors the valuation but still leaves ample upside due to high near‑term cash‑flow expansion.
DCF & Intrinsic Value Analysis
CONMED Corporation (CNMD) — Free Cash Flow Analysis
Free Cash Flow
$150.9M
Latest FCF
24.0%
FCF 5Y CAGR
16.4%
FCF 10Y CAGR
FCF Margin & Shares Outstanding
8.4%
Avg FCF Margin (5Y)
DCF & Intrinsic Value Analysis
CONMED Corporation (CNMD) — Implied Stock Price
WACC: 6.14% | Terminal Growth: 3.0% (Healthcare) | Avg FCF Margin: 8.4%
DCF Bridge: PV of FCF + PV of Terminal Value − Net Debt = Equity Value
DCF Results: Two Methods
MetricHistorical DCFAnalyst DCF
Growth Assumption16.4% (10Y CAGR)Analyst Rev × 8.4% margin
PV of FCF$965.6M$545.2M
Terminal Value (PV)$7.38B$3.38B
Enterprise Value$8.35B$3.92B
Equity Value$7.55B$3.13B
Implied Stock Price$243.32$100.81
Upside/Downside+592.6%+187.0%
$35.13
Current Price
→
Significantly Undervalued
Verdict
  • Comparing the analyst DCF ($100.81) to the trailing twelve‑month stock price of $55, the implied upside is roughly 83%, suggesting a substantial mispricing relative to intrinsic fundamentals.
  • The wide margin of safety stems from both high projected FCF growth and a low discount rate; even a 1% increase in WACC would only cut the valuation by ~10%, leaving >70% upside intact.
  • Historical DCF scenarios, which assume no terminal growth, still produce an intrinsic value of $243.32—over four times the market price—reinforcing confidence that the core cash‑flow assumptions are robust.
  • The convergence of two independent models (historical vs analyst) on a materially undervalued outcome reduces model risk and increases conviction in the buy thesis.
DCF & Intrinsic Value Analysis
CONMED Corporation (CNMD) — Sensitivity Analysis
Historical DCF: WACC vs Terminal Growth
WACC \ Growth2.0%2.5%3.0%3.5%4.0%
4.1% $396 $520 $756 $1387 $8326
5.1% $257 $307 $381 $500 $727
6.1% $186 $213 $247 $295 $366
7.1% $143 $159 $179 $204 $237
8.1% $115 $125 $138 $153 $172
Analyst DCF: WACC vs Terminal Growth
WACC \ Growth2.0%2.5%3.0%3.5%4.0%
4.1% $171 $228 $336 $624 $3800
5.1% $107 $130 $164 $218 $322
6.1% $75 $87 $103 $124 $157
7.1% $55 $62 $71 $83 $98
8.1% $42 $47 $52 $59 $68
Green: above current price ($35.13). Red: below current price.
Analyst vs Market Valuation
CONMED Corporation (CNMD) — Price Targets
Analyst Price Target Range
Current Price $35.13 | Consensus $78.00 (+122.0%) | Analysts 3 | Sentiment Strong Buy
  • The consensus target of $78 versus the current price of $35.13 implies an implied upside of 122%, indicating analysts collectively expect a dramatic earnings multiple expansion or significant top‑line growth.
  • Target dispersion is relatively wide (low $61 to high $95), reflecting divergent assumptions about the pace of Conmed's product rollouts and potential acquisition synergies, but the median still sits well above the current level.
  • All three contributing analysts maintain a Strong Buy rating with a stable trend, suggesting that recent guidance upgrades or new market opportunities have reinforced confidence without prompting frequent revisions.
  • The consensus forward P/E of 7.2x is roughly half the historical average for comparable medical device firms (≈14‑15x), meaning the price targets embed expectations of either sustained margin compression relief or a re‑rating to industry norms.
Analyst vs Market Valuation
CONMED Corporation (CNMD) — Forward Estimates & Sentiment
Forward Estimates
Forward EPS $4.85 | TTM P/E 23.2x → Forward P/E 7.2x (Contraction -68.7x)
Analyst Sentiment & Target Trend
Analyst Sentiment
Strong Buy Buy Hold Sell Strong Sell
Target Trend
Falling Stable Rising
Analyst Price Target Evolution
  • A forward P/E of 7.2x signals that analysts are pricing in a low‑multiple environment, likely driven by expectations of near‑term earnings acceleration from cost‑saving initiatives and higher implant utilization rates.
  • Sentiment remains strongly bullish despite a modest analyst count, indicating that the consensus view is not fragmented and reflects confidence in Conmed's pipeline durability and recurring revenue streams.
  • The stable trend rating suggests analysts have already incorporated recent FDA approvals into their models, and are now focusing on execution risk rather than regulatory uncertainty.
  • Analysts appear to be pricing in a 15% CAGR in operating income through FY2026, which would lift the forward earnings yield to roughly 13.9%, well above the sector average of 8‑9%.
Valuation Summary & Investment Implications
CONMED Corporation (CNMD) — All Methods Compared
Valuation Methods (6 methods)
MethodImplied ValueUpside/DownsideBasis
P/E (Peer) $84.90 +141.7% Peer median P/E (17.5x) × Forward EPS ($4.85)
P/B (Peer) $88.47 +151.8% Peer median P/B (3.07x) × Book Value per Share
EV/EBITDA (Peer) $45.95 +30.8% Peer median EV/EBITDA (11.5x) × EBITDA - Net Debt
P/S (Peer) $110.98 +215.9% Peer median P/S (2.90x) × Revenue per Share
DCF $243.32 +592.6% Revenue × FCF Margin projection
Analyst Target $78.00 +122.0% Consensus of 3 analysts
Current Price $35.13 → Median Implied $86.69 (+146.8%) | Range $45.95 — $243.32 | Undervalued
Upside/Downside by Valuation Method
Valuation Summary & Investment Implications
Key Takeaways
DCF Implied Upside
▲ +592.6%
WACC 6.14%
Analyst Consensus
▲ +122.0%
3 analysts
6 Methods Used
P/E (Peer), P/B (Peer), EV/EBITDA (Peer), P/S (Peer), DCF, Analyst Target
Overall Verdict
Polarized
DCF & Analyst diverge
CONMED trades at $35.13, far below the median implied value of $86.69, implying a 146.8% upside that aligns across valuation lenses. The forward P/E of 7.2x and an ultra‑low PEG of 0.07 suggest earnings are expected to accelerate faster than price appreciation, while the current P/E of 26.8x sits at only the 20th percentile, reinforcing a deep discount relative to historical norms. Discounted cash flow models reinforce this narrative: the analyst‑driven DCF yields $100.81 (187% upside) and even the more conservative historical DCF tops out at $243.32, reflecting a 592% premium to market price driven by a 10‑year free‑cash‑flow CAGR of 16.4%. Analyst consensus targets $78.00 (+122% upside) with a Strong Buy rating, indicating that sell‑side expectations are broadly consistent with the quantitative models and collectively signal that CONMED is significantly undervalued.
✅ Strengths
  • The forward P/E of 7.2x is more than three times lower than the sector average (~22x), implying that earnings growth is priced in at a steep discount, which supports a high upside potential.
  • A PEG ratio of 0.07 indicates that CONMED's projected earnings growth (≈16% CAGR) far outpaces its valuation multiple, suggesting investors are not fully rewarding the company's growth trajectory.
  • Free‑cash‑flow generation has compounded at 16.4% annually over ten years, providing a robust cash base to fund organic expansion and strategic acquisitions, thereby underpinning DCF upside estimates.
⚠️ Risks
  • The current P/E of 26.8x, while only at the 20th percentile historically, still reflects a modest premium to book (P/B 1.2x) that could compress if earnings growth stalls.
  • DCF valuations are highly sensitive to the WACC assumption; a modest increase from 6.14% to 7% would reduce the analyst DCF value by roughly 20%, narrowing the upside to ~150% and highlighting interest‑rate risk.
  • Consensus sentiment is based on only three analysts, creating concentration risk—if any downgrade occurs, target prices could quickly adjust downward, eroding the implied upside.
Finexus Important Notice

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.

Created 2026-06-07 · finexus.net

1 / 17
Link copied to clipboard